Efficacy of SJ733 in Adults With Uncomplicated Plasmodium Falciparum or Vivax Malaria

Malaria, Falciparum Clinical Trial

Official title:

An Open Label Phase 2a Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of (+)-SJ000557733 (SJ733) With or Without Cobicistat in Adult Patients With Acute, Uncomplicated Malaria Over a 42 Day Period

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04709692
• Other study ID #: 53333
• Status: Completed
• Phase: Phase 2
• Start date: April 14, 2021
• Est. completion date: April 15, 2022

Study information

• Verified date: November 2023
• Source: University of Kentucky
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This Phase 2a trial recruits adult patients with uncomplicated P. vivax or P. falciparum blood-stage malaria mono-infection. The study drug SJ733 will be administered to examine its antimalarial efficacy, safety, and tolerability. This study also evaluates whether or not a fixed dose of the pharmacoenhancer cobicistat when given in combination with SJ733 significantly improves drug efficacy.

Description:

This is an adaptive open label Phase 2a study to examine the antimalarial efficacy, safety, and tolerability of SJ733 in adult patients with uncomplicated P. vivax or P. falciparum blood-stage malaria monoinfection. SJ733 will be administered orally once every day for three consecutive days, with or without a fixed dose of the pharmacoenhancer cobicistat. The Phase 1 clinical data (completed under a US IND) and PK/PD models suggest that SJ733 is most likely to be curative as a 3-daily-dose pharmacoenhanced therapy, due to its moderately rapid clearance. There will be 1-3 cohorts with each cohort containing two treatment arms, P. falciparum (a) and P. vivax (b). Cohort progression will be managed independently for each treatment arm. Interim analysis will determine whether the data for a given treatment arm meets the success criteria, is inconclusive, or meets the failure criteria. Antimalarial efficacy will be examined over the period of 42 days. Additional aims are to characterize the safety and pharmacokinetics of SJ733. The results of this trial will identify active, well-tolerated doses for investigation in a larger Phase 2b clinical trial.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 22
• Est. completion date: April 15, 2022
• Est. primary completion date: April 15, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Male or female, aged 18 to 70 years of age (inclusive) at screening.

2. Body weight between 45 kg and 90 kg inclusive

3. Presence of mono-infection of P. falciparum or P. vivax confirmed by:

1. Fever, as defined by axillary temperature = 37.5°C or oral/rectal/tympanic temperature = 38°C, or history of fever in the previous 24 hours (history of fever must be documented) and,

2. Microscopically confirmed parasite infection: 1,000 to 40,000 asexual parasite count/µL blood

4. Written informed consent provided by participant, in accordance with local practice. If the participant is unable to write, witnessed consent is permitted according to local ethical considerations.

5. Ability to swallow oral medication.

6. Ability and willingness to participate and to comply with the study requirements

7. Agreement to hospitalization for at least 102 hours and/or until malarial parasites are not detected by microscopy on 2 consecutive occasions.

8. Agreement to come back to the hospital on Days 7, 10 or 11, 14, 17 or 18, 21, 24 or 25, 28, 35, and 42.

9. Women of child-bearing potential, has a negative pregnancy test at screening, and agrees to comply with one of the following during the treatment stage of the study and

for a period of 90 days after stopping study drug:

1. Use of oral, implantable, or injectable hormonal contraceptive, either combined or progestogen alone used in conjunction with barrier method as defined below.

2. Use of an intrauterine device with a documented failure rate of <1% per year.

3. Barrier method consisting of either condom or diaphragm.

4. Male partner who is sterile prior to the female subject's entry into the study and is the sole sexual partner for that female.

5. Complete abstinence from intercourse for 2 weeks prior to administration of study drug, throughout the study and for a period of 90 days after stopping study drug.

Exclusion Criteria:

1. Signs and symptoms of severe/complicated malaria according to the World Health Organization Criteria 2010 (Attachment 1: Definition of Severe Malaria)

2. Mixed Plasmodium infection.

3. Severe vomiting, defined as more than three times in the 24 hours prior to inclusion in the study, or severe diarrhea defined as 3 or more watery stools per day.

4. Severe malnutrition (defined as the weight-for-height being below -3 standard deviation or less than 70% of median of the NCHS/WHO normalized reference values)

5. Presence of a significant medical or psychiatric condition, or any other serious or chronic clinical condition requiring hospitalization, or any other condition that in the opinion of the investigator precludes participation in the study.

6. Female patients must not be either lactating or pregnant as demonstrated by a negative serum point-of-care pregnancy test pre-dose (the result of the pre-dose assessment must be confirmed negative prior to dosing).

7. Employment under the direct supervision of the investigators or study staff.

8. Clinically significant alterations to hematologic or clinical chemistry parameters that in the opinion of the investigator precludes participation in the study,

including:

1. AST/ALT > 3 x upper limit of normal range (ULN) and total bilirubin is normal

2. AST/ALT > 2 x ULN and total bilirubin is >1 and <1.5 x ULN and conjugated bilirubin is > 35% of the total bilirubin

3. Total bilirubin > 1.5 x ULN

4. Serum creatinine levels > 2 x ULN

5. Hb level < 8 g/dL

6. Platelet level < 50,000/mm3

9. Participation in a clinical study of another investigational small molecule within 30 days or investigational biologic within 90 days prior to study enrollment or planning to begin such participation during the study.

10. Have received any antimalarial treatment (alone or in combination) in the past

containing:

1. Piperaquine, mefloquine, naphthoquine or sulphadoxine / pyrimethamine within the previous 6 weeks

2. Amodiaquine or chloroquine within the previous 4 weeks

3. Any artemisinin (artesunate, artemether, arteether or dihydroartemisinin) quinine, halofantrine, lumefantrine and any other anti-malarial treatment or antibiotics with antimalarial activity (including cotrimoxazole, tetracyclines, quinolones and fluoroquinolones, and azithromycin) within the past 14 days

11. Any medication from the list of prohibited medications.

Related Conditions & MeSH terms

• Malaria
• Malaria, Falciparum
• Malaria, Vivax

Intervention

Drug:
• (+)-SJ000557733 (SJ733)
Anti-Malarial

Locations

Country	Name	City	State
Peru	Asociación Civil Selva Amazónica (ACSA)	Iquitos	Loreto

Sponsors (4)

Lead Sponsor	Collaborator
R. Kiplin Guy	Asociacion Civil Selva Amazonica, Eisai Inc., Global Health Innovative Technology Fund

Country where clinical trial is conducted

Peru, 

References & Publications (2)

Gaur AH, McCarthy JS, Panetta JC, Dallas RH, Woodford J, Tang L, Smith AM, Stewart TB, Branum KC, Freeman BB 3rd, Patel ND, John E, Chalon S, Ost S, Heine RN, Richardson JL, Christensen R, Flynn PM, Van Gessel Y, Mitasev B, Mohrle JJ, Gusovsky F, Bebrevska L, Guy RK. Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial. Lancet Infect Dis. 2020 Aug;20(8):964-975. doi: 10.1016/S1473-3099(19)30611-5. Epub 2020 Apr 8. — View Citation

Jimenez-Diaz MB, Ebert D, Salinas Y, Pradhan A, Lehane AM, Myrand-Lapierre ME, O'Loughlin KG, Shackleford DM, Justino de Almeida M, Carrillo AK, Clark JA, Dennis AS, Diep J, Deng X, Duffy S, Endsley AN, Fedewa G, Guiguemde WA, Gomez MG, Holbrook G, Horst J, Kim CC, Liu J, Lee MC, Matheny A, Martinez MS, Miller G, Rodriguez-Alejandre A, Sanz L, Sigal M, Spillman NJ, Stein PD, Wang Z, Zhu F, Waterson D, Knapp S, Shelat A, Avery VM, Fidock DA, Gamo FJ, Charman SA, Mirsalis JC, Ma H, Ferrer S, Kirk K, Angulo-Barturen I, Kyle DE, DeRisi JL, Floyd DM, Guy RK. (+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium. Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):E5455-62. doi: 10.1073/pnas.1414221111. Epub 2014 Dec 1. Erratum In: Proc Natl Acad Sci U S A. 2015 Oct 20;112(42):E5764. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Crude Adequate Clinical and Parasitological Response (ACPR), PCR Adjusted, at Days 7, 14, 28, 35, and 42	Crude Adequate Clinical and Parasitological Response (ACPR) as adjusted by quantitative PCR of parasite DNA at Days 7, 14, 28, 35, and 42	42 days for each arm
Other	Time to Recurrence of Malaria Infection, PCR Adjusted	Time to recurrence of either P. vivax or P. falciparum malaria as measured by PCR	42 days for each arm
Primary	Crude Adequate Clinical and Parasitological Response (ACPR)	Crude Adequate Clinical and Parasitological Response (ACPR) defined as the absence of microscopically determined parasitemia (thick smear).	14 days for each arm
Primary	Percent of Patients With Treatment Related Adverse Events	Number of and seriousness of treatment related adverse events as defined in Adult Toxicity Tables	42 days for each arm
Primary	Percent of Patients With Clinically Significant Abnormal Laboratory Values	Number of and seriousness of clinically significant abnormal laboratory values including changes from baseline in (biochemistry and hematology)	42 days for each arm
Primary	Percent of Patients With Clinically Significant Abnormal Vital Signs	Number of and seriousness of clinically significant abnormal vital signs including changes from baseline	42 days for each arm
Primary	Percent of Patients With a Decrease in Hemoglobin (HB) > 2 g/dL From Baseline to an Absolute Value of < 5 g/dL	Percent of patients with a decrease in hemoglobin (HB) > 2 g/dL from baseline to an absolute value of < 5 g/dL	42 days
Primary	Percent of Patients With an Absolute Neutrophil Count < 1,000/µL After Baseline	Percent of patients with an absolute Neutrophil count < 1,000/µL after baseline	42 days
Primary	Percent of Patients Meeting Hy's Law Criteria	Percent of patients meeting Hy's law criteria. Hy's law criteria: (1) Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) elevation of >3× the upper limit of normal (ULN); (2) total bilirubin (TBL) elevation of >2× ULN; (3) absence of initial findings of cholestasis (ie, absence of elevation of alkaline phosphatase [ALP] to >2× ULN); and (4) no other reason can be found to explain the combination of increased ALT and TBL, such as viral hepatitis A through E; other preexisting or acute liver disease; or another drug capable of causing the observed injury.	42 days
Primary	Percent of Patients With Any ALT or AST = 5 x ULN	Percent of patients with Any ALT or AST = 5 x upper limit of normal (ULN)	42 days
Primary	Percent of Patients With a ny AST or ALT = 3 x ULN Together With the Appearance of Fatigue, Nausea, Vomiting, Right Upper Quadrant Pain or Tenderness, Fever, Rash and/or Eosinophilia	Percent of patients with any AST or ALT = 3 x ULN together with the appearance of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash and/or eosinophilia (eosinophil percent or count above the upper limit of normal (ULN))	42 days
Primary	Percent of Patients With Persistent ALT = 3 x ULN for a Period of More Than 4 Weeks.	Percent of patients with persistent ALT = 3 x ULN for a period of more than 4 weeks.	42 days
Primary	Percent of Patients With Clinical Signs of Possible Cutaneous Adverse Reactions	Percent of patients with clinical signs of possible cutaneous adverse reactions such as dermatitis, rash, erythematous rash, macular rash, papular rash, maculo-papular rash, pruritic rash, pustular rash, vesicular rash	42 days
Primary	Percent of Patients With Clinically Significant Increases in Venous Methemoglobin Levels	Percent of patients with clinically significant increases in venous methemoglobin levels	42 days
Primary	Percent of Patients With Significant Changes in ECG Findings	Percent of patients with significant changes in ECG findings, including heart rate, ECG intervals (PR, QTcB, QTcF), conduction changes or abnormalities	42 days
Secondary	Number of Participants With Signs and Symptoms of Uncomplicated Malaria	Number of participants with symptoms (including fever) or physical examination signs related to uncomplicated P. vivax or P. falciparum malaria	42 days for each arm
Secondary	Parasite Clearance Time	Time to parasite clearance as measured by microscopy	42 days for each arm
Secondary	Parasite Reduction Rate	The parasite reduction rate is calculated as the slope of the linear portion of the regression fit of natural log of average parasitemia (per microliter) versus time (in hours). Reported slope is representative of all analyzed participants in each arm. Slope is analyzed during time frame in which there is active reduction of parasitemia by treatment (0->96 h).	0->96 h, depending upon the time required to reach lower limit of detection
Secondary	Asexual Parasite Clearance Time	Time to clearance of asexual parasites as measured by microscopy including half life of clearance. Clearance time represents the time at which the mean parasitemia has reached the given threshold for the arm/cohort. For PC100, the value represents the time at which all patients have undetectable parasitemia.	42 days for each arm
Secondary	Percent Change in Asexual Parasites From Baseline	Percentage change of asexual parasites as determined by microscopy, relative to baseline at the specified times. The value represents the average parasitemia in the arm/cohort at the given time (per microliter) versus time (in hours) compared to the average parasitemia at T0. Reported reduction is representative of all analyzed participants in each arm.	42 days
Secondary	Area Under the Plasma Concentration-time Curve (AUC)	AUC of SJ733 and its metabolite SJ506 will be reported	11 days for each arm
Secondary	Maximum Plasma Drug Concentration (Cmax)	Cmax of SJ733 and its metabolite SJ506 will be reported	11 days for each arm
Secondary	Time to Reach Maximum Plasma Concentration (Tmax)	Time to reach maximum plasma concentration (Tmax) of SJ733 will be reported	11 days for each arm
Secondary	Drug Clearance	Drug clearance of SJ733 and its metabolite SJ506 will be reported	11 days for each arm
Secondary	Crude Adequate Clinical and Parasitological Response (ACPR) at Days 28, 35, and 42	Crude Adequate Clinical and Parasitological Response (ACPR) at Days 28, 35, and 42 as measured by microscopy.	42 days for each arm
Secondary	Time to Recurrence of Malaria Infection	Time to recurrence of either P. vivax or P. falciparum malaria as measured by signs and symptoms or malaria and microscopy	42 days for each arm
Secondary	Fever Clearance Time	Time from baseline to the first of two consecutive post-dose auxiliary temperature measurements < 37.5 C obtained within an interval of 4 to 24 hours of each other	42 days for each arm